Showing 6491-6500 of 20414 results for "".
Therapeutic Advances and Fighting for Authorizations
https://reachmd.com/programs/practical-dermatology/therapeutic-advances-and-fighting-for-authorizations/35890/Joel L. Cohen, MD, FAAD, and Leon Kircik, MD, FAAD, discuss the latest developments in psoriasis and atopic dermatitis, as well as the challenges involved with fighting for prior authorizations for the best therapies, at Music City SCALE 2025.Recognizing Asthma-COPD Overlap: Clinical Clues and Diagnostic Strategies
https://reachmd.com/programs/frontlines-copd/recognizing-asthma-copd-overlap-clinical-clues-and-diagnostic-strategies/35541/Since asthma-COPD overlap syndrome combines features of two distinct respiratory diseases, there’s no single diagnostic test available. And so clinicians must integrate biomarkers and testing strategies from both disease frameworks to properly assess these complex cases. Here to share key strategiesPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 2
https://reachmd.com/programs/practical-dermatology/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-2/32758/Host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, discuss the differences between psoriasis subtypes, the importance of a specialized therapeutic approach targeting the IL-36 pathway for generalized pustular psoriasis, and the role of neutrophiScalp Psoriasis Treatment: Examining Deucravacitinib’s Efficacy and Safety
https://reachmd.com/programs/frontlines-psoriasis/scalp-psoriasis-treatment-examining-deucravacitinibs-efficacy-and-safety/32429/Dive into the efficacy and safety of deucravacitinib, a selective TYK2 inhibitor that has shown favorable outcomes in treating scalp psoriasis.Transforming Schizophrenia Treatment: Advances in Medication and Therapy
https://reachmd.com/programs/neurofrontiers/transforming-schizophrenia-treatment-advances-in-medication-and-therapy/27073/Dive into emerging schizophrenia treatments, including promising new medications.Reviewing Updated Guidelines and Knowledge Gaps for Pouchitis Management
https://reachmd.com/programs/gi-insights/reviewing-updated-guidelines-and-knowledge-gaps-for-pouchitis-management/16591/Tune in as we review the AGA’s updated guidelines on pouchitis and inflammatory pouch disorders.Supporting the Peripartum Period Through Perinatal Psychiatry
https://reachmd.com/programs/neurofrontiers/supporting-the-peripartum-period-through-perinatal-psychiatry/15947/Perinatal mental health conditions are widely undetected and undertreated. Tune into this Psych Congress recap of the importance of perinatal psychiatry.Recognizing & Addressing the Burden of COPD Exacerbations
https://reachmd.com/programs/deep-breaths-updates-chest/recognizing-addressing-the-burden-of-copd-exacerbations/14161/Learn about recognizing COPD exacerbations and implementing strategies that are critical for limiting exacerbation burden.Exploring Marijuana Use in Psychopharmacology: A Look Ahead at the Psych Congress
https://reachmd.com/programs/psych-congress-action-center/exploring-marijuana-use-in-psychopharmacology-a-look-ahead-at-the-psych-congress/14197/At Psych Congress 2022, psychiatrists from around the world tackled everything impacting the field of psychopharmacology, including the use of cannabis. What do we need to know about marijuana as a treatment option?What to Know About the No Surprises Act
https://reachmd.com/programs/perspectives-ama/what-to-know-about-the-no-surprises-act/12791/How will the No Surprises Act help protect consumers from surprise medical bills, and what’s the current status of its implementation?